Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jul 24 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Ibrutinib tablets in various strengths. Ibrutinib is a medication used for treating specific types of blood cancers. The tablets will be manufactured at Zydus's facility in Ahmedabad, and the product had significant annual sales in the United States. This approval adds to Zydus's growing portfolio, with a total of approvals and applications filed since the start of their filing process.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 24, 2025, titled "Zydus receives tentative approval from USFDA for Ibrutinib tablets 140 mg, 280 mg, and 420 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases